Enliven Therapeutics (ELVN) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 9, 2026, to be held virtually for stockholders of record as of April 10, 2026.

• Proxy materials, including the notice, proxy statement, and annual report, are available online or by request.

Voting matters and shareholder proposals

• Election of two Class III directors to serve until the 2029 annual meeting or until successors are qualified.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Amendment to increase authorized common stock from 100,000,000 to 200,000,000 shares.

• Advisory vote on executive compensation as disclosed in the proxy statement.

• Advisory vote on the frequency of future say-on-pay votes, with a recommendation for annual votes.

Board of directors and corporate governance

• Board recommends voting for Richard Fair, M.B.A., and Lori Kunkel, M.D., as Class III directors.